OUR CAPABILITIES

Support for every research milestone.

Clinical Study Management

We offer Phase I, II and III clinical trial design, planning and execution utilizing a data-driven, flexible and efficient approach. Using innovative and precise methods for capturing and analyzing data, we identify early signals of response to put your oncology therapy on the path to approval.

learn more +

Preclinical

In the early phase of oncology research, TD2 sets you up for success with an extensive suite of preclinical tools, over 400 models of cancer as well as extensive knowledge in designing and adapting your study to maximize data value and predict patient response.

Learn more +

Regulatory Support

Your medicine’s journey to approval requires a veteran team dedicated to navigating each phase of development. At TD2, we manage the most complex aspects of the regulatory process including IND readiness assessment, program evaluation, IND development and filings, and all FDA interactions.

learn more +

PK/ADME

Drug metabolism and pharmacokinetic(DMPK) analyses are key to successful drug development and approval, and TD2 can help determine which tests are the best fit early through a diverse set of assays to support your program.

Learn more +

Cutting-Edge Resources

Minimize risk during
drug development.

Protect your project against risk and give your new agents the greatest chance of success with our advanced scientific tools built around tumor models, combination strategies and mutational context identification. After all, the future of oncology therapeutic discovery depends on accurately defining the clinical research strategy that will give your treatment an advantage in the clinic and then aligning that strategy with execution.

REGULATORY FILINGS

An impact on modern-day oncology.

Born from the Translational Genomics Research Institute (TGen), TD2 was formed in 2003 as a subsidiary of TGen. Less than two years later, we opened our doors on the campus of the Mayo Clinic in Scottsdale, Arizona. TD2 has helped more than 600 biotech and pharma companies in nearly two decades, maintaining hundreds of client studies per year. Among them, our team has been involved in more than 600 first-in-man major oncology medicines, including numerous clinical trials that have led to approvals in both rare and large indications.

HELPED
MORE THAN

850

biotech and
pharma companies

INVOLVED IN
MORE THAN

600

first-in-man major
oncology medicines

TRANSITIONED
MORE THAN

100

companies from our
laboratories into
clinical trials

GET STARTED

Ask us how you can get your oncology medicine to market faster with TD2.